Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by analysts at BTIG Research in a report released on Tuesday, Benzinga reports. They presently have a $151.00 price objective on the stock. BTIG Research‘s price target indicates a potential upside of 44.41% from the company’s current price.

ORKA has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, September 3rd. Wedbush reaffirmed an “outperform” rating and set a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $104.56 on Tuesday. The firm has a 50-day simple moving average of $88.48 and a 200-day simple moving average of $70.92. Oruka Therapeutics has a one year low of $25.23 and a one year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). On average, research analysts forecast that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the completion of the sale, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This represents a 39.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total value of $734,143.86. Following the completion of the sale, the insider directly owned 31,771 shares of the company’s stock, valued at $2,935,004.98. The trade was a 20.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 179,950 shares of company stock valued at $16,492,680. 23.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. Virtus Advisers LLC boosted its holdings in Oruka Therapeutics by 25.0% in the third quarter. Virtus Advisers LLC now owns 5,908 shares of the company’s stock worth $492,000 after acquiring an additional 1,182 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Oruka Therapeutics by 217.6% during the third quarter. Fisher Asset Management LLC now owns 215,593 shares of the company’s stock valued at $17,957,000 after acquiring an additional 147,719 shares in the last quarter. Knights of Columbus Asset Advisors LLC acquired a new position in shares of Oruka Therapeutics during the third quarter valued at about $1,166,000. Allspring Global Investments Holdings LLC raised its position in shares of Oruka Therapeutics by 4.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,991 shares of the company’s stock valued at $333,000 after purchasing an additional 168 shares during the last quarter. Finally, Ethic Inc. raised its position in shares of Oruka Therapeutics by 12.3% in the 3rd quarter. Ethic Inc. now owns 3,329 shares of the company’s stock valued at $277,000 after purchasing an additional 364 shares during the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments.

The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.

Oruka was established around antibody programs developed by Paragon Therapeutics and became a publicly traded company in 2024 through a business combination with ARCA biopharma.